PIC
BBIO icon

Portland Investment Counsel’s BridgeBio Pharma BBIO Stock Holding History

Portland Investment Counsel’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$382K – 53
2024
Q3 		$382K Hold
15,000
– – 0.14% 40
2024
Q2 		$380K Buy
15,000
+8,000
+114% +$219K 0.14% 42
2024
Q1 		$905 Buy
+7,000
New +$238K 0.27% 30

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Portland Investment Counsel's BBIO Position: Q4 2024 in Review

Portland Investment Counsel sold out of BridgeBio Pharma (BBIO) in Q4 2024, closing a stake of 15,000 shares — an estimated $382K sold.

Portland Investment Counsel first reported a position in BBIO in Q1 2024 and held it in 3 quarters. The position peaked at $382K in Q3 2024. 263 funds tracked by Wall St. Rank hold BBIO as of Q4 2024.

  • Portland Investment Counsel reported no remaining BridgeBio Pharma position as of Q4 2024 after selling out during the quarter.
  • Portland Investment Counsel sold 15,000 BridgeBio Pharma shares in Q4 2024, an estimated $382K.
  • Portland Investment Counsel first reported a position in BridgeBio Pharma in Q1 2024 and held it in 3 quarters.
  • Portland Investment Counsel's BridgeBio Pharma position peaked at $382K in Q3 2024.
  • 263 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2024.

Based on Portland Investment Counsel's 13F filing for Q4 2024, filed 14 Feb 2025.